Pure Global
NCT06120374

Adjuvant Radiotherapy and Combined Adjuvant Treatment Strategy for UTUC

Safety and Efficacy of Adjuvant Radiotherapy and Combined Adjuvant Treatment Strategy for Upper Tract Urothelial Carcinoma: An Ambispective Cohort Study
Peking University First Hospital·ClinicalTrials.gov·radiationRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Urothelial Carcinoma
Drug/Device/Intervention
Radiotherapy
Study type
Observational
Intervention type
radiation
Sponsor & location
Primary sponsor
Peking University First Hospital
Location
Beijing,Beijing,Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Oct 30, 2023
End date
Oct 30, 2028
Enrollment
300 participants
Primary outcome

PFS

Summary

This study is an ambispective cohort observational study to analyze the efficacy of surgery
 alone versus postoperative adjuvant therapy (postoperative radiotherapy/postoperative
 chemotherapy(immunotherapy)/ combined strategy) in patients with the upper urinary tract
 urothelial carcinoma with high-risk factors (postoperative pathology suggestive of pT2 and
 above, N+, G3/high-grade and multiple tumors, positive cut margins). A subgroup analysis was
 performed to obtain the population of patients who might benefit from different treatment
 approaches. Patients with high risk factors for postoperative recurrence or metastasis will
 be treated with relevant adjuvant therapy, which in turn will benefit patients.

ICD-10 classifications
Carcinoma in situ: Other and unspecified urinary organsMalignant neoplasm of ureterMalignant neoplasms of urinary tractMalignant neoplasm: Overlapping lesion of urinary organsMalignant neoplasm: Urethra
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06120374
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06120374 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University First Hospital and is currently Recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.